Instruments to Evaluate Self-Management of Radiation Dermatitis in Patients With Breast Cancer

Pembroke, Michelle; Nemeth, Lynne S.

doi:10.1188/20.onf.101-111

Cited by 6 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Frequent and accurate assessment of symptoms and functions is an essential element for the care of patients with cancer, in which patient-reported outcome (PRO) measures have been a gold standard to quantify patients’ subjective experience [ 2 ]. Valid and reliable PRO measures are vital for patient-centered care among those with breast cancer, as they play an important role in enhancing patient-nurse communication and assisting nurses in systematically monitoring and managing patients’ symptoms [ 1 , 3 ]. In addition, such assessments enable the prediction of the symptom trajectory for this vulnerable sample [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Validity and reliability of the Chinese version of the Patient-Reported Outcomes Measurement Information System adult profile-57 (PROMIS-57)

Cai

Huang

et al. 2022

Health Qual Life Outcomes

View full text Add to dashboard Cite

Background The PROMIS-57 is a commonly used self-reported instrument to solve the lack of generalizable and universal measures required to evaluate common symptoms and functions from patients’ perspectives. This study aimed to translate the PROMIS-57 into Chinese and psychometrically test the translated instrument on patients with breast cancer. Methods Translation, cross‑cultural adaptation, and psychometric evaluation of the instrument were performed from June 2020 to June 2021. Eligible patients were recruited and completed the PROMIS-57, Functional Assessment of Cancer Therapy-Breast (FACT-B), and a sociodemographic questionnaire. Results Data from 602 patients with a mean age of 48.83 years were analyzed. Most domains in the PROMIS-57 showed an absence of floor and ceiling effects. Multi-trait scaling analysis demonstrated acceptable convergent and discriminant validity. The correlations between the PROMIS-57 scores and the selected FACT-B scores supported the criterion validity via the Pearson correlation test. Measurement invariance was supported by the absence of differential item functioning for most items. Cronbach’s α of the domains ranged from 0.85–0.95. The unidimensional factor structure of all domains was supported using confirmatory factor analyses. Additionally, most items showed acceptable item information curves and item characteristics curve matrices. Conclusion The Chinese version of the PROMIS-57 was found to be a reliable and valid tool for assessing common symptoms and functions among patients with breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Validity and reliability of the Chinese version of the Patient-Reported Outcomes Measurement Information System adult profile-57 (PROMIS-57)

Cai

Huang

et al. 2022

Health Qual Life Outcomes

View full text Add to dashboard Cite

show abstract

“…Because breast tissue is superficial and sensitive to radiotherapy, it is typically used as adjuvant therapy after BC surgery, such as breast-conserving surgery or radical mastectomy [ 24 , 25 ]. Radiotherapy reduces the risk of local recurrence of BC significantly [ 26 ], but it also causes radiation dermatitis, radiation pneumonia, bone marrow suppression, heart and lung injury, and radiation-induced malignancy [ 27 , 28 , 29 ].…”

Section: Clinical Therapymentioning

confidence: 99%

Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer

Sun

Liu

et al. 2022

Cancers

View full text Add to dashboard Cite

Breast cancer (BC) is the most common malignancy in women worldwide, and it is a molecularly diverse disease. Heterogeneity can be observed in a wide range of cell types with varying morphologies and behaviors. Molecular classifications are broadly used in clinical diagnosis, including estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and breast cancer gene (BRCA) mutations, as indicators of tumor heterogeneity. Treatment strategies differ according to the molecular subtype. Besides the traditional treatments, such as hormone (endocrine) therapy, radiotherapy, and chemotherapy, innovative approaches have accelerated BC treatments, which contain targeted therapies and immunotherapy. Among them, monoclonal antibodies, small-molecule inhibitors and antibody–drug conjugates, and targeted delivery systems are promising armamentarium for breast cancer, while checkpoint inhibitors, CAR T cell therapy, cancer vaccines, and tumor-microenvironment-targeted therapy provide a more comprehensive understanding of breast cancer and could assist in developing new therapeutic strategies.

show abstract

Comparison of clinical practice guidelines on radiation dermatitis: a narrative review

Finkelstein

Kanee

Behroozian

et al. 2022

Support Care Cancer

View full text Add to dashboard Cite

Instruments to Evaluate Self-Management of Radiation Dermatitis in Patients With Breast Cancer

Cited by 6 publications

References 30 publications

Validity and reliability of the Chinese version of the Patient-Reported Outcomes Measurement Information System adult profile-57 (PROMIS-57)

Validity and reliability of the Chinese version of the Patient-Reported Outcomes Measurement Information System adult profile-57 (PROMIS-57)

Targeted Therapy and Immunotherapy for Heterogeneous Breast Cancer

Comparison of clinical practice guidelines on radiation dermatitis: a narrative review

Contact Info

Product

Resources

About